| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stephen Aronson, Bart Van Baelen, Shane Kavanagh, Susanne Schwale. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs & aging. vol 26. issue 3. 2009-06-04. PMID:19358618. |
galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the alzheimer's type. |
2009-06-04 |
2023-08-12 |
Not clear |
| Mohammad Diab, Jacquelyn Coloe, Mark A Bechte. Bullous pemphigoid precipitated by galantamine hydrobromide. Cutis. vol 83. issue 3. 2009-05-28. PMID:19363906. |
we report a case of drug-induced bp (dibp) likely due to galantamine hydrobromide, a competitive and reversible acetylcholinesterase inhibitor used in the treatment of mild to moderate alzheimer dementia. |
2009-05-28 |
2023-08-12 |
Not clear |
| Howard H Feldman, Claudia Jacov. Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come? Nature clinical practice. Neurology. vol 5. issue 3. 2009-05-13. PMID:19190589. |
predicting response to acetylcholinesterase inhibitor treatment in alzheimer disease: has the time come? |
2009-05-13 |
2023-08-12 |
Not clear |
| Yong Zhu, Xin-Yue Tong, Yue Zhao, Hui Chen, Feng-Chao Jian. Construction of the pharmacophore model of acetylcholinesterase inhibitor. Yao xue xue bao = Acta pharmaceutica Sinica. vol 43. issue 3. 2009-05-11. PMID:18630262. |
this pharmacophore model will act on the double active site of acetylcholinesterase and is able to predict the activity of known acetylcholinesterase inhibitors that are used for clinical treatment of alzheimer's disease (ad), and can be further used to identify structurally diverse compounds that have higher activity treating with alzheimer's disease (ad) by virtual screening. |
2009-05-11 |
2023-08-12 |
Not clear |
| Agneta Nordberg, Taher Darreh-Shori, Elaine Peskind, Hilkka Soininen, Malahat Mousavi, Gina Eagle, Roger Lan. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Current Alzheimer research. vol 6. issue 1. 2009-05-08. PMID:19199870. |
the current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (ache) and butyrylcholinesterase (buche) activities and protein levels, in the cerebrospinal fluid (csf) of alzheimer disease (ad) patients. |
2009-05-08 |
2023-08-12 |
Not clear |
| Mario F Mende. Frontotemporal dementia: therapeutic interventions. Frontiers of neurology and neuroscience. vol 24. 2009-04-30. PMID:19182475. |
the acetylcholinesterase inhibitors used for patients with alzheimer's disease have not had significant efficacy for patients with ftd, but memantine, another dementia medication, is under investigation for the treatment of this disorder. |
2009-04-30 |
2023-08-12 |
Not clear |
| Yuki Takada-Takatori, Toshiaki Kume, Yasuhiko Izumi, Yuta Ohgi, Tetsuhiro Niidome, Takeshi Fujii, Hachiro Sugimoto, Akinori Akaik. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biological & pharmaceutical bulletin. vol 32. issue 3. 2009-04-28. PMID:19252271. |
donepezil, galantamine and tacrine are acetylcholinesterase inhibitors used for the treatment of alzheimer's disease, and were believed to be symptomatic drugs whose therapeutic effects are achieved by slowing the hydrolysis of acetylcholine at synaptic termini. |
2009-04-28 |
2023-08-12 |
rat |
| Touqeer Ahmed, Anwarul-Hassan Gilan. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacology, biochemistry, and behavior. vol 91. issue 4. 2009-04-23. PMID:18930076. |
inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in alzheimer's disease. |
2009-04-23 |
2023-08-12 |
rat |
| Min-Young Noh, Seong-Ho Koh, Youngchul Kim, Hyun Young Kim, Goang Won Cho, Seung Hyun Ki. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. Journal of neurochemistry. vol 108. issue 5. 2009-04-22. PMID:19077054. |
acetylcholinesterase inhibitors (ache-inhibitors) are used for the treatment of alzheimer's disease. |
2009-04-22 |
2023-08-12 |
rat |
| Jung-Eun Park, Soon-Tae Lee, Woo-Seok Im, Kon Chu, Manho Ki. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease. Neuroscience letters. vol 448. issue 1. 2009-04-16. PMID:18938211. |
the acetylcholinesterase inhibitor (achei) galantamine is currently used to treat mild to moderate alzheimer's disease (ad), and it has been suggested to have several neuroprotective effects. |
2009-04-16 |
2023-08-12 |
rat |
| Luca Rozzini, Barbara Vicini Chilovi, Erik Bertoletti, Diego Ghianda, Marta Conti, Marco Trabucchi, Alessandro Padovan. Serum albumin level interferes with the effect of donepezil in Alzheimer's disease. Aging clinical and experimental research. vol 20. issue 6. 2009-03-30. PMID:19179833. |
the most successful therapeutic approaches to alzheimer's disease (ad) have involved acetylcholinesterase inhibitors (cheis). |
2009-03-30 |
2023-08-12 |
Not clear |
| Peter T Nelson, Richard J Kryscio, Erin L Abner, Frederick A Schmitt, Gregory A Jicha, Marta S Mendiondo, Greg Cooper, Charles B Smith, William R Markesber. Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB. Journal of Alzheimer's disease : JAD. vol 16. issue 1. 2009-03-27. PMID:19158418. |
acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with alzheimer's disease and ad + dlb. |
2009-03-27 |
2023-08-12 |
Not clear |
| Steen G Hasselbalch, Jens Peter Kampman. [Treatment of degenerative dementia disorders--who should be treated?]. Ugeskrift for laeger. vol 171. issue 10. 2009-03-17. PMID:19265606. |
such evidence supports treatment of mild to moderate alzheimer's disease (ad) with acetylcholinesterase inhibitors (achei), and moderate to severe ad with memantine. |
2009-03-17 |
2023-08-12 |
Not clear |
| Silvia Lorrio, Pilar Negredo, José M Roda, Antonio G García, Manuela G Lópe. Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. Brain research. vol 1254. 2009-03-13. PMID:19103181. |
galantamine is an acetylcholinesterase inhibitor and memantine is a non competitive antagonist of nmda receptors that are being used to treat alzheimer's disease (ad) patients. |
2009-03-13 |
2023-08-12 |
Not clear |
| Martina Zimmermann, Martin S Westwell, Susan A Greenfiel. Impact of detergents on the activity of acetylcholinesterase and on the effectiveness of its inhibitors. Biological chemistry. vol 390. issue 1. 2009-03-12. PMID:19007306. |
acetylcholinesterase (ache) plays a central role in the development of alzheimer's disease: ache inhibition for preventing the characteristic dwindling of acetylcholine levels constitutes the current standard treatment for the disorder. |
2009-03-12 |
2023-08-12 |
Not clear |
| You Yin, Liuqing Huang, Yan Liu, Shaqi Huang, JianHua Zhuang, Xiaoyan Chen, Lin Zhang, Huijuan Wu, Fuyuan Shao, Zhongxin Zha. Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer's disease rat model. Clinical and investigative medicine. Medecine clinique et experimentale. vol 31. issue 5. 2009-03-10. PMID:18980714. |
effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of alzheimer's disease rat model. |
2009-03-10 |
2023-08-12 |
rat |
| You Yin, Liuqing Huang, Yan Liu, Shaqi Huang, JianHua Zhuang, Xiaoyan Chen, Lin Zhang, Huijuan Wu, Fuyuan Shao, Zhongxin Zha. Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer's disease rat model. Clinical and investigative medicine. Medecine clinique et experimentale. vol 31. issue 5. 2009-03-10. PMID:18980714. |
to determine the influence of tanshinone on the levels of nitric oxide synthase (nos) and acetylcholinesterase (ache) in the brain of an alzheimer's disease (ad) rat model and on its potential therapeutic mechanism. |
2009-03-10 |
2023-08-12 |
rat |
| E Salmo. [A transdermal patch of rivastigmine (Exelon)]. Revue medicale de Liege. vol 63. issue 9. 2009-02-25. PMID:19051514. |
inhibitors of acetylcholinesterase provide a modest symptomatic benefit for a majority of patients with alzheimer's disease. |
2009-02-25 |
2023-08-12 |
Not clear |
| Ivo J C Vieira, Walter L B Medeiros, Cecilia S Monnerat, Jucimar J Souza, Leda Mathias, Raimundo Braz-Filho, Angelo C Pinto, Priscila M Sousa, Claudia M Rezende, Rosângela de A Epifani. Two fast screening methods (GC-MS and TLC-ChEI assay) for rapid evaluation of potential anticholinesterasic indole alkaloids in complex mixtures. Anais da Academia Brasileira de Ciencias. vol 80. issue 3. 2009-02-23. PMID:18797794. |
the pharmacotherapy for alzheimer's disease (ad) includes the use of acetylcholinesterase inhibitors (achei). |
2009-02-23 |
2023-08-12 |
Not clear |
| Christian Fleck, Dorothea Appenroth, Michael Decker, Jochen Lehman. A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy. Arzneimittel-Forschung. vol 58. issue 11. 2009-02-23. PMID:19137904. |
six new tri- and tetracyclic nitrogen bridgehead compounds known to be moderate to potent inhibitors of acetylcholinesterase (ache) and butyrylcholinesterase (bche) in vitro were tested in vivo as experimental therapeutics for treatment of alzheimer's disease. |
2009-02-23 |
2023-08-12 |
rat |